Overview

Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

Status:
Not yet recruiting

Trial end date:
2027-04-01

Target enrollment:

Participant gender:

Summary

This is a single-arm, uncontrolled, international, multi-center, clinical,phase 2 trial, in patients ≥ 12 months of age with high-risk neuroblastoma in first remission. 120 patients will be enrolled to receive naxitamab + GM-CSF in combination with isotretinoin.

Phase:

Phase 2

Details

Lead Sponsor:

Y-mAbs Therapeutics

Treatments:

Isotretinoin